SciELO - Scientific Electronic Library Online

 
vol.51 número5Boron neutron capture therapy in cancer: past, present and futureWill the thyroglobulin assay with lower functional sensitivity whilst the patients are on L-T4 treatment replace the TSH-stimulated thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer? índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Arquivos Brasileiros de Endocrinologia & Metabologia

versión impresa ISSN 0004-2730

Resumen

SANTORO, Massimo  y  FUSCO, Alfredo. New drugs in thyroid cancer. Arq Bras Endocrinol Metab [online]. 2007, vol.51, n.5, pp. 857-861. ISSN 0004-2730.  http://dx.doi.org/10.1590/S0004-27302007000500025.

This review is focused on "new drugs" that might be developed for thyroid cancer treatment. Thyroid cancer is frequently associated to the activation of specific protein (RET, BRAF) and lipid [PI(3)K] kinases. There is good evidence that these genetic lesions are causative events in thyroid cancer initiation or progression. Therefore, novel compounds able to target these kinases might be useful for thyroid cancer treatment. The power of this approach is witnessed by the examples of BCR-ABL, c-KIT and EGFR inhibitors in the treatment of chronic myelogenous leukemia (CML), gastro-intestinal stromal tumors (GIST) and non-small cell lung carcinoma (NSCLC).

Palabras llave : Thyroid cancer; Lipid kinases; RET; BRAF; Cancer therapy.

        · resumen en Portugués     · texto en Inglés     · pdf en Inglés